Dermata Therapeutics (DRMA) Profit After Tax (2020 - 2026)

Dermata Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 19.79% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$7.1 million (up 38.0% YoY), while the FY2025 annual figure was -$7.6 million, up 38.49% from the prior year.
• Profit After Tax for Q1 2026 stood at -$1.8 million, up from -$1.9 million in the prior quarter.
• The five-year high for Profit After Tax was -$1.7 million in Q4 2022, with the low at -$3.2 million in Q3 2024.
• The 5-year median for Profit After Tax is -$2.2 million (2023), against an average of -$2.3 million.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax sank 105.03% in 2022, then surged 46.68% in 2025.
• Dermata Therapeutics' Profit After Tax stood at -$1.7 million in 2022, then dropped by 27.81% to -$2.1 million in 2023, then tumbled by 47.66% to -$3.2 million in 2024, then jumped by 40.91% to -$1.9 million in 2025, then gained by 0.76% to -$1.8 million in 2026.
• Business Quant data shows DRMA's Profit After Tax at -$1.8 million in Q1 2026, -$1.9 million in Q4 2025, and -$1.7 million in Q3 2025.